Efficacy and safety analysis of oxaliplatin-based chemotherapy for advanced gastric cancer

Kyoko Inadomi, Hitoshi Kusaba, Yuzo Matsushita, Risa Tanaka, Kenji Mitsugi, Kohei Arimizu, Gen Hirano, Akitaka Makiyama, Hirofumi Ohmura, Keita Uchino, Fumiyasu Hanamura, Yoshihiro Shibata, Miyuki Kuwayama, Taito Esaki, Kotoe Takayoshi, Shuji Arita, Hiroshi Ariyama, Koichi Akashi, Eishi Baba

研究成果: ジャーナルへの寄稿記事

4 引用 (Scopus)

抄録

Background: Significant efficacy of oxaliplatinbased chemotherapy has been demonstrated for advanced gastric cancer (AGC). However, the appropriate dose of oxaliplatin, and the efficacy and toxicity of administration of oxaliplatin subsequent to cisplatin therapy still remain unclear. Patients and Methods: In total, 55 patients with AGC that were scheduled to receive oxaliplatin-based chemotherapy were prospectively examined. Results: The median age was 67 years and oxaliplatin was administered to 39 (71%) patients as first-line and in 16 (29%) patients as second-line therapy. An initial dose of 130 or 100 mg/m2 of oxaliplatin was administered to 11 and 36 patients, respectively. The overall response rates (ORR) and median progression free survival (mPFS) were 86 and 33%, and 7.2 and 7.8 months, respectively. Compared to 100 mg/m2, the relative dose intensity was significantly lower and severe toxicity tended to increase with oxaliplatin at 130 mg/m2. A total of 10 patients (18%) had a prior cisplatin-based therapy. The ORR of the patients pretreated with cisplatin was 14% and the mPFS was 6.1 months. Conclusion: An initial oxaliplatin dose of 130 mg/m2 resulted in a good response, but tended to increase the risk of toxicity. Subsequent oxaliplatin-based therapy after cisplatin exhibited modest efficacy, especially in cases with cisplatin intolerance.

元の言語英語
ページ(範囲)2663-2671
ページ数9
ジャーナルAnticancer research
37
発行部数5
DOI
出版物ステータス出版済み - 5 2017

Fingerprint

oxaliplatin
Stomach Neoplasms
Safety
Drug Therapy
Cisplatin
Disease-Free Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Efficacy and safety analysis of oxaliplatin-based chemotherapy for advanced gastric cancer. / Inadomi, Kyoko; Kusaba, Hitoshi; Matsushita, Yuzo; Tanaka, Risa; Mitsugi, Kenji; Arimizu, Kohei; Hirano, Gen; Makiyama, Akitaka; Ohmura, Hirofumi; Uchino, Keita; Hanamura, Fumiyasu; Shibata, Yoshihiro; Kuwayama, Miyuki; Esaki, Taito; Takayoshi, Kotoe; Arita, Shuji; Ariyama, Hiroshi; Akashi, Koichi; Baba, Eishi.

:: Anticancer research, 巻 37, 番号 5, 05.2017, p. 2663-2671.

研究成果: ジャーナルへの寄稿記事

Inadomi, K, Kusaba, H, Matsushita, Y, Tanaka, R, Mitsugi, K, Arimizu, K, Hirano, G, Makiyama, A, Ohmura, H, Uchino, K, Hanamura, F, Shibata, Y, Kuwayama, M, Esaki, T, Takayoshi, K, Arita, S, Ariyama, H, Akashi, K & Baba, E 2017, 'Efficacy and safety analysis of oxaliplatin-based chemotherapy for advanced gastric cancer', Anticancer research, 巻. 37, 番号 5, pp. 2663-2671. https://doi.org/10.21873/anticanres.11614
Inadomi, Kyoko ; Kusaba, Hitoshi ; Matsushita, Yuzo ; Tanaka, Risa ; Mitsugi, Kenji ; Arimizu, Kohei ; Hirano, Gen ; Makiyama, Akitaka ; Ohmura, Hirofumi ; Uchino, Keita ; Hanamura, Fumiyasu ; Shibata, Yoshihiro ; Kuwayama, Miyuki ; Esaki, Taito ; Takayoshi, Kotoe ; Arita, Shuji ; Ariyama, Hiroshi ; Akashi, Koichi ; Baba, Eishi. / Efficacy and safety analysis of oxaliplatin-based chemotherapy for advanced gastric cancer. :: Anticancer research. 2017 ; 巻 37, 番号 5. pp. 2663-2671.
@article{97add75a94f142f2b18745f1743a3cd7,
title = "Efficacy and safety analysis of oxaliplatin-based chemotherapy for advanced gastric cancer",
abstract = "Background: Significant efficacy of oxaliplatinbased chemotherapy has been demonstrated for advanced gastric cancer (AGC). However, the appropriate dose of oxaliplatin, and the efficacy and toxicity of administration of oxaliplatin subsequent to cisplatin therapy still remain unclear. Patients and Methods: In total, 55 patients with AGC that were scheduled to receive oxaliplatin-based chemotherapy were prospectively examined. Results: The median age was 67 years and oxaliplatin was administered to 39 (71{\%}) patients as first-line and in 16 (29{\%}) patients as second-line therapy. An initial dose of 130 or 100 mg/m2 of oxaliplatin was administered to 11 and 36 patients, respectively. The overall response rates (ORR) and median progression free survival (mPFS) were 86 and 33{\%}, and 7.2 and 7.8 months, respectively. Compared to 100 mg/m2, the relative dose intensity was significantly lower and severe toxicity tended to increase with oxaliplatin at 130 mg/m2. A total of 10 patients (18{\%}) had a prior cisplatin-based therapy. The ORR of the patients pretreated with cisplatin was 14{\%} and the mPFS was 6.1 months. Conclusion: An initial oxaliplatin dose of 130 mg/m2 resulted in a good response, but tended to increase the risk of toxicity. Subsequent oxaliplatin-based therapy after cisplatin exhibited modest efficacy, especially in cases with cisplatin intolerance.",
author = "Kyoko Inadomi and Hitoshi Kusaba and Yuzo Matsushita and Risa Tanaka and Kenji Mitsugi and Kohei Arimizu and Gen Hirano and Akitaka Makiyama and Hirofumi Ohmura and Keita Uchino and Fumiyasu Hanamura and Yoshihiro Shibata and Miyuki Kuwayama and Taito Esaki and Kotoe Takayoshi and Shuji Arita and Hiroshi Ariyama and Koichi Akashi and Eishi Baba",
year = "2017",
month = "5",
doi = "10.21873/anticanres.11614",
language = "English",
volume = "37",
pages = "2663--2671",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Efficacy and safety analysis of oxaliplatin-based chemotherapy for advanced gastric cancer

AU - Inadomi, Kyoko

AU - Kusaba, Hitoshi

AU - Matsushita, Yuzo

AU - Tanaka, Risa

AU - Mitsugi, Kenji

AU - Arimizu, Kohei

AU - Hirano, Gen

AU - Makiyama, Akitaka

AU - Ohmura, Hirofumi

AU - Uchino, Keita

AU - Hanamura, Fumiyasu

AU - Shibata, Yoshihiro

AU - Kuwayama, Miyuki

AU - Esaki, Taito

AU - Takayoshi, Kotoe

AU - Arita, Shuji

AU - Ariyama, Hiroshi

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2017/5

Y1 - 2017/5

N2 - Background: Significant efficacy of oxaliplatinbased chemotherapy has been demonstrated for advanced gastric cancer (AGC). However, the appropriate dose of oxaliplatin, and the efficacy and toxicity of administration of oxaliplatin subsequent to cisplatin therapy still remain unclear. Patients and Methods: In total, 55 patients with AGC that were scheduled to receive oxaliplatin-based chemotherapy were prospectively examined. Results: The median age was 67 years and oxaliplatin was administered to 39 (71%) patients as first-line and in 16 (29%) patients as second-line therapy. An initial dose of 130 or 100 mg/m2 of oxaliplatin was administered to 11 and 36 patients, respectively. The overall response rates (ORR) and median progression free survival (mPFS) were 86 and 33%, and 7.2 and 7.8 months, respectively. Compared to 100 mg/m2, the relative dose intensity was significantly lower and severe toxicity tended to increase with oxaliplatin at 130 mg/m2. A total of 10 patients (18%) had a prior cisplatin-based therapy. The ORR of the patients pretreated with cisplatin was 14% and the mPFS was 6.1 months. Conclusion: An initial oxaliplatin dose of 130 mg/m2 resulted in a good response, but tended to increase the risk of toxicity. Subsequent oxaliplatin-based therapy after cisplatin exhibited modest efficacy, especially in cases with cisplatin intolerance.

AB - Background: Significant efficacy of oxaliplatinbased chemotherapy has been demonstrated for advanced gastric cancer (AGC). However, the appropriate dose of oxaliplatin, and the efficacy and toxicity of administration of oxaliplatin subsequent to cisplatin therapy still remain unclear. Patients and Methods: In total, 55 patients with AGC that were scheduled to receive oxaliplatin-based chemotherapy were prospectively examined. Results: The median age was 67 years and oxaliplatin was administered to 39 (71%) patients as first-line and in 16 (29%) patients as second-line therapy. An initial dose of 130 or 100 mg/m2 of oxaliplatin was administered to 11 and 36 patients, respectively. The overall response rates (ORR) and median progression free survival (mPFS) were 86 and 33%, and 7.2 and 7.8 months, respectively. Compared to 100 mg/m2, the relative dose intensity was significantly lower and severe toxicity tended to increase with oxaliplatin at 130 mg/m2. A total of 10 patients (18%) had a prior cisplatin-based therapy. The ORR of the patients pretreated with cisplatin was 14% and the mPFS was 6.1 months. Conclusion: An initial oxaliplatin dose of 130 mg/m2 resulted in a good response, but tended to increase the risk of toxicity. Subsequent oxaliplatin-based therapy after cisplatin exhibited modest efficacy, especially in cases with cisplatin intolerance.

UR - http://www.scopus.com/inward/record.url?scp=85019133798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019133798&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11614

DO - 10.21873/anticanres.11614

M3 - Article

C2 - 28476842

AN - SCOPUS:85019133798

VL - 37

SP - 2663

EP - 2671

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -